Symptoms of the progressive cholestatic liver disease primary biliary cholangitis (PBC) include pruritus and fatigue. Pruritus can persist chronically in at least one-third of people with PBC and can range from mild to severe, with fluctuations over time, including on a daily basis. Proposed causative factors for PBC-associated pruritus include bile acids, lysophosphatidic acid (LPA), and endogenous opioids, with proposed symptom mechanisms linked to increases of these substances, or associated pathways. All offer potential routes for drug treatment to help alleviate pruritus in some patients. PBC-associated pruritus can have a significantly detrimental effect on a person’s quality of life (QoL) due to a sometimes constant feeling of ‘bugs crawling’ on their skin, and the need to ‘tear my skin off’. Pruritus may lead to secondary skin lesions, embarrassment, and social isolation. Pruritus is associated with sleep deprivation and subsequent daytime tiredness and fatigue, as well as depression, and sometimes in the worst cases, leading to suicide. Treatments for PBC-associated pruritus include bile acid sequestrants, rifampicin, opioid antagonists, sertraline, and gabapentin, as well as topical moisturisers, behavioural changes, and ultraviolet light therapy. Though not currently approved for such, ileal bile acid transporter (IBAT) inhibitors are undergoing clinical trials, as success in alleviating pruritus is shown in similar conditions. In patients where PBC-associated pruritus is very severe, liver transplantation is a consideration. At the 2023 European Association for the Study of the Liver (EASL) Congress, leading experts in the field of PBC, including clinician-researchers, a nurse specialist, and a representative from the PBC Foundation, highlighted the importance of discussing, assessing, and treating pruritus in people with PBC, using a holistic approach to understanding and caring for this QoL-affecting symptom.